University of Utah Research Foundation

Maxion Therapeutics Limited

Iontas Limited

Tim Luetkens

Michael Richard Dyson

Sachin Badrinath Surade

Djordje Atanackovic

Sabarinath Venniyil Radhakrishnan

John Mccafferty

Aneesh Karatt Vellatt

Edward William Masters

Damian Colin Bell

Binding members for sodium channel Nav1.7 and their use in medicine including for treatment of pain or epilepsy. Binding members comprise a fusion protein containing a Nav1.7-binding peptide, e.g., venom toxin peptide or knottin ('donor diversity scaffold domain') inserted within an antibody variable domain (“recipient diversity scaffold domain”), and a partner domain (e.g., antibody variable domain), optionally wherein the partner domain enhances specificity of binding to Nav1.7 over other sodium channels.

Sodium channel inhibitors

Disclosed are chimeric antigen receptor (CAR) polypeptides comprising a CD229 antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Disclosed are nucleic acid sequences capable of encoding a CAR polypeptide comprising a CD229 antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Also disclosed are vectors and cells comprising one or both of the CAR polypeptides and nucleic acid sequences capable of encoding CAR polypeptides. Also disclosed are methods of treating.

CD229 CAR T cells and methods of use thereof

Growing community of inventors

Salt Lake City, UT, United States of America

Tim Luetkens